Shareholders approve reverse stock split, dilutive share issuances, and 2025 equity plan at cbdMD annual meeting

cbdMD, Inc.

Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
Approved issuance of >20% of outstanding shares upon conversion of Series B and Series C Preferred and under ELOC with C/M Capital.
2025 Equity Compensation Plan approved with 891,316 initial shares plus 2% annual evergreen (max 300,000/year).
CEO Kennedy receives 445,000 restricted shares under the newly approved plan.
All seven director nominees elected; Cherry Bekaert LLP ratified as auditor for FY2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.